Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IOVA vs BIIB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: IOVA 1 – 5 BIIB Matrix Metrics: IOVA 2 – 8 BIIB

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IOVA carries a Unified Composite Score of 70.4/100 (BUY) at $7.63 (N/M Forward P/E, -60.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin).

  • Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (70.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. -60.8% operating margin) and revenue trajectory (+10.6% vs. +80.1% YoY).
  • Technical & Structure Timing Caution: IOVA is currently in a Breakdown options structure phase (RSI 32.5); meanwhile BIIB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IOVA vs BIIB
IOVA NASDAQ
Iovance Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.63
-1.71% 1D
Market Cap $3.5B
TTM Revenue $379M
Forward P/E N/M
Beta / 30D Vol 1.58β · 144% Vol
Unified Composite Score
70.4 / 100 BUY
Tech 80.0 Fund 70.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 32
RSI-14: 32.5 · SMA20: $10.38 · SMA50: $11.31
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03

6-Pillar Scorecard Institutional Category Breakdown (IOVA 1 – 5 BIIB)

Columns: Metric · IOVA · BIIB
1. Valuation Multiples BIIB
Forward P/E N/M 15.6x
Trailing P/E N/M 109.9x
PEG Ratio N/M 3.45x
EV / Revenue 9.3x 4.2x
2. Growth & Scale IOVA
Revenue Growth (YoY) +80.1% +10.6%
Earnings Growth (YoY) +0.0% -84.8%
TTM Revenue (USD) $379M $10.3B
Market Cap $3.5B $37.0B
3. Profitability & Quality BIIB
Gross Margin 53.2% 75.8%
Operating Margin -60.8% 23.5%
Net Profit Margin -58.2% 3.4%
Return on Equity (ROE) -29.1% 1.9%
4. Balance Sheet & Cash Flow BIIB
Cash Generation (TTM) -$216M $1.64B
Cash Flow Margin -57.0% 16.0%
Net Cash / Leverage $13M Net Cash $6.50B Net Debt (0.41x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BIIB
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 83.9% (25th %ile) 18.4% (6th %ile)
Put/Call OI Skew 0.58x (Call-Skewed) 0.77x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat BIIB
OpEx & R&D Intensity N/A 52.3% of Rev ($5.39B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IOVA (2) vs BIIB (8)
Institutional Metric IOVA BIIB Criterion Row Edge
Market Capitalization
Scale
$3.5B $37.0B Larger Scale BIIB
Trailing P/E Ratio
Valuation
N/M 109.9x Lower Multiple BIIB
Forward P/E Ratio
Valuation
N/M 15.6x Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+80.1% +10.6% Higher Growth IOVA
Operating Margin (TTM)
Profitability
-60.8% 23.5% Higher Margin BIIB
Net Profit Margin
Profitability
-58.2% 3.4% Higher Margin BIIB
Return on Equity (ROE)
Capital Efficiency
-29.1% 1.9% Higher ROE BIIB
52-Week Range Position
Momentum
42% ($2–$15) 92% ($160–$261) Stronger Trend BIIB
Beta / 30D Volatility
Risk Regime
1.58β · 144% Vol 0.27β · 36% Vol Lower Realized Risk BIIB
Unified Institutional Score
Composite Signal
70.4 / 100 (BUY) 50.2 / 100 (HOLD) Higher Composite IOVA
Trailing 12M Revenue (USD)
Operating Scale
$379M $10.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.2% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.3x EV/Rev 3.45x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$216M ($13M Net Cash) $1.64B ($6.50B Net Debt (0.41x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +52.63 pp
IOVA: -44.0% · BIIB: +8.63%
3M Horizon BIIB +10.41 pp
IOVA: +8.49% · BIIB: +18.9%
6M Horizon IOVA +93.3 pp
IOVA: +124.99% · BIIB: +31.69%
1Y Horizon IOVA +163.06 pp
IOVA: +216.47% · BIIB: +53.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IOVA Revenue BIIB Revenue IOVA Op. Margin BIIB Op. Margin Margin Leader
FY2018 N/A $13.4B N/A 43.8% BIIB
FY2019 N/A $14.4B N/A 49.0% BIIB
FY2020 N/A $13.4B N/A 33.8% BIIB
FY2021 N/A $11.0B N/A 25.9% BIIB
FY2022 N/A $10.2B N/A 29.9% BIIB
FY2023 $0M $9.84B -38735.0% 11.8% BIIB
FY2024 $160M $9.68B -240.9% 16.9% BIIB
FY2025 $260M $9.89B -153.1% 13.1% BIIB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IOVA BREAKDOWN
33d in phase · OBV NEUTRAL
Current IV 83.9%
IV Percentile 25th %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IOVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IOVA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and -60.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published

Investor FAQ IOVA vs BIIB Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IOVA carries a Unified Composite Score of 70.4/100 (BUY) at $7.63 (N/M Forward P/E, -60.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin). Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (70.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. -60.8% operating margin) and revenue trajectory (+10.6% vs. +80.1% YoY). Technical & Structure Timing Caution: IOVA is currently in a Breakdown options structure phase (RSI 32.5); meanwhile BIIB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IOVA leads the Growth & Scale pillar: IOVA posts +80.1% YoY revenue growth and +0.0% YoY earnings growth on $379M TTM revenue (53.2% gross margin, -60.8% operating margin), compared with BIIB at +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IOVA cumulative revenue shifted +62.5% while BIIB shifted -26.5%. In operating R&D and SG&A reinvestment, IOVA deploys N/A (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($5.39B) (0 disclosures) for BIIB.

BIIB screens cheaper on headline valuation multiples. IOVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.3x EV/Revenue (-57.0% FCF margin), whereas BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IOVA (-29.1% ROE) versus BIIB (1.9% ROE) capital efficiency.

In options market volatility and institutional positioning, IOVA carries 83.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 144% Vol realized risk). By comparison, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.